Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT00944905 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma
Non-hodgkin's Lymphoma

Interventions

BIOLOGICAL: MDX-1203

Sponsor

Bristol-Myers Squibb